Skip to main content

Abeona Therapeutics Inc.

corporate_fare Company Profile

Abeona Therapeutics Inc.

ABEO·NASDAQ·Life Sciences·CIK 0000318306

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for life-threatening diseases. On April 28, 2025, the U.S. Food and Drug Administration (FDA) approved ZEVASKYN ® (prademagene zamikeracel) gene-modified cellular sheets, also known as ZEVASKYN ® , as the first and only autologous cell-based gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and debilitating genetic skin disease. ZEVASKYN ® is the only FDA-approved product to treat RDEB wounds with a single surgical application and was granted Orphan Drug and Rare Pediatric Disease designations by the FDA. ZEVASKYN ® is manufactured at the company's current Good Manufacturing Practices (cGMP) facility in Cleveland, Ohio. Treatments are provided through ZEVASKYN ® qualified treatment centers, a network selected for their expertise in cell and gene therapy and trained to administer ZEVASKYN ® . As of March 2026, Abeona has activated 4 qualified treatment centers and is expanding this network. The company's development portfolio also includes adeno-associated virus (AAV)-based gene therapies designed to treat ophthalmic diseases with high unmet need using novel AIM™ capsids. Abeona partners with academic researchers, patient advocacy organizations, caregivers, and other biotechnology companies to develop therapies for rare genetic diseases lacking effective treatment options. The company's strategy involves commercializing ZEVASKYN ® and advancing and commercializing its cell and gene therapy programs.

Abeona Therapeutics Inc. (NASDAQ:ABEO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ABEO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for ABEO spans 10-Q, 8-K, SCHEDULE 13D, 144.

Recent high-impact activity:

  • Abeona Q3: ZEVASKYN Revenue $13.5M, Net Loss Narrows to $4.8M, $134.9M Cash
  • Abeona Buys Phase 3 EoE Drug, Raises $30M at $3.75 a Share
  • Abeona Q3: ZEVASKYN Revenue $13.5M, Net Loss Narrows to $4.8M, Cash $134.9M
  • Abeona Posts $13.5M in Q3 Revenue, Topping Q2's $11.4M
  • Abeona Buys Phase 3-Ready ABO-801 for $20M Stock, Raises $30M PIPE at $3.75

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$5.82M
Net Income
$71.18M
Diluted EPS
$1.01
Op. Cash Flow
-$76.33M
Free Cash Flow
-$84.3M
Gross Profit
$4.29M
Operating Income
-$89.45M
Cash & Equivalents
$78.44M
Total Debt
$20.04M
Debt / Equity
0.13×
Net Margin
12.23×
Shares Outstanding
55.04M sh
Source: 10-K · filed 2026-03-17 · accession 0001493152-26-010413

Short Interest & Short Volume

21.67 days to cover

FINRA reported short interest of 16,879,896 shares in ABEO as of the October 30, 2026 settlement, a 1.9% decrease from the prior period — about 21.7 days to cover at its recent average daily volume. On November 20, 2026, 19.2% of ABEO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)16,879,896 shares as of October 30, 2026
Change vs prior period▼ 1.9%
Days to cover21.67 at avg daily volume of 778,947
Daily short volume (FINRA facilities)19.2% of 2,985,588 shares on November 20, 2026
5-day average short volume31.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ABEO, detected from its recent SEC filings.

1 shelf registration

Resale Shelf Covers 12.49M Shares · Placement Priced at $3.75

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$2.42
52-week range · as of 2026-11-09 $2.3 – $7.65
Market cap
$138.3M
Volume
4.7M (2.3× avg)
3-mo avg 2.1M
Live data · 2026-11-22 06:01 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ABEO - Latest Insights

ABEO
Nov 09, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $2.42 info
Change: -$0.100 (-4%) info
Market Cap: $138.295M info
ABEO
Nov 09, 2026, 11:06 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $2.62
Real-time Price: $2.42 info
Change: -$0.195 (-7%) info
Market Cap: $138.295M info
ABEO
Nov 09, 2026, 6:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $2.42 info
Change: -$1.59 (-40%) info
Market Cap: $138.295M info
ABEO
Nov 09, 2026, 6:35 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $2.42 info
Change: -$1.59 (-40%) info
Market Cap: $138.295M info
ABEO
Nov 09, 2026, 6:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $2.42 info
Change: -$1.76 (-42%) info
Market Cap: $138.295M info
ABEO
Nov 09, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $2.42 info
Change: -$1.76 (-42%) info
Market Cap: $138.295M info
ABEO
Oct 23, 2026, 2:38 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $4.32
Real-time Price: $2.42 info
Change: -$1.90 (-44%) info
Market Cap: $138.295M info
ABEO
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.40
Real-time Price: $2.42 info
Change: -$2.98 (-55%) info
Market Cap: $138.295M info
ABEO
Sep 18, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.74
Real-time Price: $2.42 info
Change: -$3.32 (-58%) info
Market Cap: $138.295M info
ABEO
Aug 13, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.60
Real-time Price: $2.42 info
Change: -$5.18 (-68%) info
Market Cap: $138.295M info
ABEO
Aug 13, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.75
Real-time Price: $2.42 info
Change: -$5.33 (-69%) info
Market Cap: $138.295M info
ABEO
Aug 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.66
Real-time Price: $2.42 info
Change: -$4.24 (-64%) info
Market Cap: $138.295M info
ABEO
Jul 06, 2026, 4:12 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $6.31
Real-time Price: $2.42 info
Change: -$3.89 (-62%) info
Market Cap: $138.295M info
ABEO
Jun 12, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.53
Real-time Price: $2.42 info
Change: -$3.11 (-56%) info
Market Cap: $138.295M info
ABEO
Jun 12, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.49
Real-time Price: $2.42 info
Change: -$3.07 (-56%) info
Market Cap: $138.295M info
ABEO
Jun 10, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.36
Real-time Price: $2.42 info
Change: -$2.94 (-55%) info
Market Cap: $138.295M info
ABEO
May 13, 2026, 7:35 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.98
Real-time Price: $2.42 info
Change: -$3.56 (-60%) info
Market Cap: $138.295M info
ABEO
May 13, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.85
Real-time Price: $2.42 info
Change: -$3.43 (-59%) info
Market Cap: $138.295M info
ABEO
May 04, 2026, 4:55 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $5.97
Real-time Price: $2.42 info
Change: -$3.55 (-59%) info
Market Cap: $138.295M info
ABEO
Apr 27, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $5.34
Real-time Price: $2.42 info
Change: -$2.92 (-55%) info
Market Cap: $138.295M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets